Status:
RECRUITING
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Alzheimer Disease
Eligibility:
All Genders
15+ years
Brief Summary
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Eligibility Criteria
Inclusion
- Patients diagnosed with Alzheimer's disease
Exclusion
- \-
Key Trial Info
Start Date :
April 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 23 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06875986
Start Date
April 17 2025
End Date
September 23 2028
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacovigilance Department
Osaka, Osaka, Japan, 540-0021